<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370240</url>
  </required_header>
  <id_info>
    <org_study_id>(CRH 05353A)</org_study_id>
    <secondary_id>EudraCT 2005-005691-32</secondary_id>
    <nct_id>NCT00370240</nct_id>
  </id_info>
  <brief_title>Chlorhydrate of Ropivacaine and Breast Cancer Surgery</brief_title>
  <official_title>Efficacy of Infiltration of Chlorhydrate of Ropivacaine in the Prevention of Chronic Breast Pain After Surgery for Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of local anesthetic (chlorhydrate of
      ropivacaine) to prevent chronic pain after breast surgery for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 20-65% of women treated with breast surgery for breast cancer experience chronic
      pain in the treated breast. Patients will be randomize between: infiltration with
      chlorhydrate of ropivacaine at the time of breast surgery for cancer versus
      placebo.Intra-operative analgesia will be standardized as well as peri-operative pain
      management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing the frequencies of chronic breast pain 3 months after breast surgery evaluated by the Brief Pain Inventory in the two groups.</measure>
    <time_frame>3 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogic Scale, Patient satisfaction with analgesic, consumption, neuropathic pain and depression/anxiety rating scale</measure>
    <time_frame>2 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Pain,Postoperative</condition>
  <arm_group>
    <arm_group_label>Ropivacaïne</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhydrate de Ropivacaine</intervention_name>
    <description>The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)</description>
    <arm_group_label>Ropivacaïne</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The PCB group received saline solution in equal volume.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer patients treated by conservative surgery with axillary node dissection
             or treated by mastectomy with or without axillary node dissection or sentinel lymph
             node biopsy.

          -  ASA physical status 1, 2 or 3

          -  With a minimum life expectancy of 2 years

          -  Written informed consent

        Exclusion Criteria:

          -  Any previous cancer other than breast cancer

          -  Allergies to local anesthesic and morphine

          -  Reported history of drug

          -  Pregnancy

          -  Homolateral breast surgery during the last 3 years

          -  Analgesic use pre-operatively

          -  Renal, pulmonary or liver major dysfunction

          -  Active malignant disease

          -  Unable to follow the protocol for any reason
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aline H Albi-Feldzer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre René Huguenin - Saint-Cloud - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>René Huguenin Center</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2006</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Female</keyword>
  <keyword>Anesthetics,local</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

